JKB 133
Alternative Names: JKB-133; TJC-0133Latest Information Update: 28 Apr 2023
At a glance
- Originator TaiwanJ Pharmaceuticals
- Developer Newsoara Biopharma; TaiwanJ Pharmaceuticals
- Class Anti-inflammatories; Hepatoprotectants; Small molecules
- Mechanism of Action Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune hepatitis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Autoimmune-hepatitis in Taiwan
- 28 Apr 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Taiwan